On the Forefront of NSCLC Treatment: Targeting RET Mutations

On the Forefront of NSCLC Treatment: Targeting RET Mutations

On the Forefront of NSCLC Treatment: Targeting RET Mutations
RestartResume

With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving.

  • Overview

    With newly approved therapies on the rise, the way we treat non-small cell lung cancer patients with a RET gene rearrangement may be evolving. That’s why it’s so important to test for RET mutations in patients with non-small cell lung cancer, as oncologist Dr. Deepa Rangachari explains.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free